首页    抗感染原料药    阿比朵尔Arbidol
4

阿比朵尔Arbidol

阿比朵尔

英文名称:Arbidol

中文别名:6-溴-5-羟基-1-甲基-4-((二甲基氨基)甲基)-2-(苯基硫甲基)-1H-吲哚-3-甲酸乙酯; 阿比多尔; 6-溴-4-(二甲氨甲基)-5-羟基-1-甲基-2-(苯硫甲基)-1H-吲哚-3-甲酸乙酯英文别名:ETHYL6-BROMO-4-((DIMETHYLAMINO)METHYL)-5-HYDROXY-1-METHYL; Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate; INTERMEDIATE:; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate; 6-bromo-4-(2-methoxy-methyl)-5-hydroxy-1-methyl-2-(S-methyl benzene)-1-Indole-3-carboxylic acid ethyl ester

CAS No.:131707-25-0

分子式:C22H25BrN2O3S

分子量:477.4145

沸点:591.8°C at 760 mmHg

蒸汽压: 1.34E-14mmHg at 25°C  

闪光点:311.7°C  

标准:企标

含量:98%

性状:类白色粉末

2020年2月4日,中国工程院院士、国家卫健委高级别专家组成员李兰娟团队,在武汉公布治疗新型冠状病毒感染的肺炎的最新研究成果。李兰娟院士表示,根据初步测试,在体外细胞实验中显示:(1)阿比朵尔在10~30微摩尔浓度下,与药物未处理的对照组比较,能有效抑制冠状病毒达到60倍,并且显著抑制病毒对细胞的病变效应。(2)达芦Chemicalbook那韦在300微摩尔浓度下,能显著抑制病毒复制,与未用药物处理组比较,抑制效率达到280倍。阿比朵尔是一种非核苷类广谱抗病毒药物,主要适应症是A类、B类流感病毒引起的流行性感冒,同时对其他一些呼吸道病毒感染可能也有抗病毒活性;2019年,阿比多尔首次被纳入国家医保目录和纳入国家卫健委发布的抗病毒流感临床推荐使用药物名单。

阿比朵尔是由前苏联药物化学研究中心研制一种双效抗流感病毒药物,能够同时对抗甲、乙型流感病毒引起的流行性感冒,同时对其他一些呼吸道病毒感染可Chemicalbook能也有抗病毒活性。1993年在俄罗斯首次上市,用于防治流行性感冒和其它急性呼吸道病毒感染。最新研究表明,阿比朵尔能有效抑制新型肺炎冠状病毒。

Abidol

English name: Arbidol

Chinese alias: 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-(phenylthiomethyl)-1H-indole-3-carboxylic acid ethyl ester; Arbidol; 6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylic acid ethyl ester English alias: ETHYL6-BROMO-4-((DIMETHYLAMINO)METHYL)-5-HYDROXY-1-METHYL; Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl ]-1H-indole-3-carboxylate; INTERMEDIATE:; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3- carboxylate; 6-bromo-4-(2-methoxy-methyl)-5-hydroxy-1-methyl-2-(S-methyl benzene)-1-Indole-3-carboxylic acid ethyl ester

CAS No.: 131707-25-0

Molecular formula: C22H25BrN2O3S

Molecular weight: 477.4145

Boiling point: 591.8°C at 760 mmHg

Vapor pressure: 1.34E-14mmHg at 25°C

Flash point: 311.7°C

Standard: Enterprise Standard

Content: 98%

Properties: off-white powder
On February 4, 2020, the team of Li Lanjuan, an academician of the Chinese Academy of Engineering and a member of the high-level expert group of the National Health Commission, announced the latest research results on the treatment of pneumonia caused by the new coronavirus in Wuhan. Academician Li Lanjuan said that according to preliminary tests, in vitro cell experiments showed that: (1) Arbidol at a concentration of 10 to 30 micromolar, compared with the untreated control group, can effectively inhibit the coronavirus by 60 times, and Significantly inhibit the pathological effects of viruses on cells. (2) Dalu Chemicalbook Navir can significantly inhibit virus replication at a concentration of 300 micromolar. Compared with the untreated group, the inhibition efficiency is 280 times. Arbidol is a non-nucleoside broad-spectrum antiviral drug. Its main indication is influenza caused by influenza A and B viruses. At the same time, it may also have antiviral activity against other respiratory virus infections; in 2019, Ah Bidol was included in the National Medical Insurance Catalog for the first time and included in the list of clinically recommended drugs for antiviral influenza issued by the National Health Commission.

Arbidol is a dual-effect anti-influenza drug developed by the former Soviet Union Medicinal Chemistry Research Center. It can simultaneously fight influenza caused by influenza A and B viruses. At the same time, it can also be anti-viral against some other respiratory virus infections. active. It was first launched in Russia in 1993 for the prevention and treatment of influenza and other acute respiratory virus infections. The latest research shows that Arbidol can effectively inhibit the new pneumonia coronavirus.